In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals Inc (EYPT), with a price target of $5. The company’s shares closed yesterday at $2.55.
Selvaraju commented:
“Our 12-month price target is derived from a market value of the firm at $462M, which includes a discounted cash flow-based asset value of $497M that includes DEXYCU, YUTIQ, and royalties from Retisert and Iluvien, with a 15% discount rate and 2% terminal growth rate, excluding $35M debt and assuming 96M shares outstanding at.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.6% and a 37.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Fennec Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for EyePoint Pharmaceuticals Inc with a $5.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.94 and a one-year low of $1.05. Currently, EyePoint Pharmaceuticals Inc has an average volume of 382K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
